Le mag’

Recommendations

Info

Behavior and E-Cigarette Exposure Fig 2. Rotarod Test. Mean latency to fall during the three training sessions. There was no difference between any of the treatment groups from day 1 through day 3. As training progressed all groups of mice demonstrated increased latencies before falling which was confirmed by ANOVA, which yielded a main effect of Day (p < 0.001). (n = 7–13) doi:10.1371/journal.pone.0137953.g002 p = 0.003) in the absence of an effect of Day or Day x Treatment interaction. Analysis of each individual day revealed mice exposed to 2.4% nicotine/PG had a greater number of rears than mice exposed to 0% nicotine/PG on both days (t- test p
Behavior and E-Cigarette Exposure Fig 3. Open Field Test. (A-B) There was a main effect of Day (F 1,25 = 4.994, p = 0.035). There was no effect of Treatment or Day x Treatment interaction. (C) t-tests were used to compare distance travelled on Day 1 between the 2.4% nicotine/PG exposed mice and each of the other two groups. Mice exposed to 2.4% nicotine/PG travelled significantly greater total distances than mice exposed to 0% nicotine/PG (t 19 = 2.205, p
Page 1 and 2:
Le mag’ 2015 Les publications sci
Page 3 and 4:
Liste des articles 1 8 23 24 26 44
Page 5 and 6:
Downloaded from http://tobaccocontr
Page 7 and 8:
Tierney PA, et al. Tob Control 2015
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
9/2/2015 PLOS ONE: Vapors Produced
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
6/6/2015 American Physiological Soc
Page 29 and 30:
Although cell studies have some val
Page 31 and 32:
Int. J. Environ. Res. Public Health
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Electronic cigarette use among curr
Page 51 and 52:
In 2015 we asked for the first time
Page 53 and 54:
Types of electronic cigarettes used
Page 55 and 56:
Perception of harm from electronic
Page 57 and 58:
Hughes et al. BMC Public Health (20
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
28/4/2015 Biochemically verified sm
Page 69 and 70:
Table of Contents 1 Background ....
Page 71 and 72:
2 The public health case - tobacco
Page 73 and 74:
People attempting to quit smoking w
Page 75 and 76:
ecent analysis shows nicotine toxic
Page 77 and 78:
nicotine products in England conclu
Page 79 and 80:
there could be independent reasons
Page 81 and 82:
arises from excessively burdensome
Page 83 and 84:
Regulatory idea Sales to minors Pro
Page 85 and 86:
4.3.4 Australia and Canada and othe
Page 87 and 88:
About the author Clive Bates runs C
Page 89 and 90:
16/4/2015 "Direct Dripping": A High
Page 91 and 92:
Lim et al The bottle had a colorful
Page 93 and 94:
Lim et al Table 2. Liquid nicotine
Page 95 and 96:
RESEARCH ARTICLE E-Cigarettes and S
Page 97 and 98:
E-Cigarettes for Smoking Cessation
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
RESEARCH REPORT doi:10.1111/add.129
Page 113 and 114:
Aldehyde emissions in e-cigarettes
Page 115 and 116:
Aldehyde emissions in e-cigarettes
Page 117 and 118:
Polosa BMC Medicine (2015) 13:54 Pa
Page 119 and 120:
Polosa BMC Medicine (2015) 13:54 Pa
Page 121 and 122:
First-Page Preview Received: 7/28/2
Page 123 and 124:
Rahman et al. Tobacco Induced Disea
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Articles in PresS. Am J Physiol Lun
Page 133 and 134:
47 48 49 50 51 52 53 54 55 56 57 58
Page 135 and 136:
93 94 95 96 97 98 99 enephosphonate
Page 137 and 138:
139 140 141 142 143 144 145 146 rat
Page 139 and 140:
184 185 Inova 500 equipped with a 5
Page 141 and 142:
216 217 218 219 220 221 222 223 224
Page 143 and 144:
262 263 264 265 266 267 268 269 270
Page 145 and 146:
308 309 310 311 312 313 314 315 316
Page 147 and 148:
354 355 356 357 358 359 360 361 362
Page 149 and 150:
400 401 402 403 404 405 406 407 408
Page 151 and 152:
432 433 434 435 436 437 438 439 440
Page 153 and 154:
474 475 476 477 478 dd; H 9a 3.24,
Page 155 and 156:
520 521 522 523 524 525 526 527 imm
Page 157 and 158:
569 570 571 572 573 574 575 576 577
Page 159 and 160:
613 614 615 616 617 618 619 620 621
Page 161 and 162:
657 658 659 660 661 662 663 664 665
Page 163 and 164:
159
Page 165 and 166:
161
Page 167 and 168:
163
Page 169 and 170:
165
Page 171 and 172:
Enquête sur l’usage de la cigare
Page 173 and 174:
Méthodes • Enquête par question
Page 175 and 176:
Expérimentation du vapotage Q2. As
Page 177 and 178:
Expérimentation du vapotage Garço
Page 179 and 180:
Obtention de la première cigarette
Page 181 and 182:
Vapotage : arômes Lorsque tu vapot
Page 183 and 184:
Tabagisme As-tu déjà fumé ? oui
Page 185 and 186:
Tabagisme % Garçons % Filles 100 1
Page 187 and 188:
Vapotage et tabagisme • lien trè
Page 189 and 190:
Vapotage et tabagisme : nicotine
Page 191 and 192:
Vapotage et sevrage tabagique Varia
Page 193 and 194:
Baromètre santé Inpes 2014 cigare
Page 195 and 196:
Conclusions • Les élèves sont d
Page 197 and 198:
Downloaded from http://bmjopen.bmj.
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
RESEARCH ARTICLE Exposure to Electr
Page 205 and 206:
E-Cigarette Exposure Impairs Pulmon
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
2 effects of smoking low-tar cigare
Page 221 and 222:
Table 1. Weighted bivariate descrip
Page 223 and 224:
6 Kaufman et al / Am J Prev Med 201
Page 225 and 226:
22/1/2015 Hidden Formaldehyde in E
Page 227 and 228:
2 Leonie S. Brose et al. with a sma
Page 229 and 230:
4 Leonie S. Brose et al. In the mai
Page 231 and 232:
6 Leonie S. Brose et al. Table 3 Ci
Page 233 and 234:
8 Leonie S. Brose et al. References
Page 235 and 236:
correspondence substantially among
Page 237 and 238:
correspondence stood; indeed, the f
Page 239 and 240:
18/6/2015 Nicotine absorption from
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
http://www.nzma.org.nz/journal/read
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
MAGNITUDE OF REDUCTION AND SMOKING
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
26/6/2015 NIOSH submits letter to t
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
INTRODUCTION Le tabac tue un fumeur
Page 295 and 296:
nitrosamines) sont de 9 à 450 fois
Page 297 and 298:
Les achats d’entreprises fabriqua
Page 299 and 300:
[10] HAS Recommandation de bonne pr
Page 301 and 302:
Exposure to Electronic Cigarette Em
Page 303 and 304:
Exposure to Electronic Cigarette Em
Page 305 and 306:
Transdisciplinary Topical Discussio
Page 307 and 308:
2015 Symposia SYM5 MAPPING BRAIN CI
Page 309 and 310:
2015 Symposia kg/infusion). Both im
Page 311 and 312:
2015 Symposia metabolizer category
Page 313 and 314:
2015 Symposia toxicant exposure. Co
Page 315 and 316:
2015 Symposia SYM15D INDIVIDUALIZED
Page 317 and 318:
2015 Symposia SYM16D RECLAIMING PUB
Page 319 and 320:
2015 Symposia SYM17D MEASURING ELEC
Page 321 and 322:
2015 Symposia expand our knowledge
Page 323 and 324:
2015 Symposia of craving and depend
Page 325 and 326:
2015 Symposia Conclusions: POP is a
Page 327 and 328:
2015 Symposia Methods: One hundred
Page 329 and 330:
2015 Paper Sessions PODIUM PRESENTA
Page 331 and 332:
2015 Paper Sessions PA12-6 INITIAL
Page 333 and 334:
2015 Paper Sessions of whom 363 (11
Page 335 and 336:
2015 Paper Sessions 2014 found wide
Page 337 and 338:
2015 Paper Sessions percent of popu
Page 339 and 340:
2015 Paper Sessions Results: We hav
Page 341 and 342:
2015 Paper Sessions PA17-5 CIGARETT
Page 343 and 344:
2015 Paper Sessions Methods: SimSmo
Page 345 and 346:
2015 Paper Sessions course of NAC (
Page 347 and 348:
2015 Paper Sessions PA3-4 UPTAKE OF
Page 349 and 350:
2015 Paper Sessions should be banne
Page 351 and 352:
2015 Paper Sessions from the Nation
Page 353 and 354:
2015 Paper Sessions and Development
Page 355 and 356:
2015 Paper Sessions min resting-sta
Page 357 and 358:
2015 Paper Sessions outlets. Method
Page 359 and 360:
2015 Paper Sessions PA5-5 BRAIN ACT
Page 361 and 362:
2015 Paper Sessions PA6-5 RESEARCH
Page 363 and 364:
2015 Paper Sessions smokers, 59.8%
Page 365 and 366:
2015 Paper Sessions intervention co
Page 367 and 368:
2015 Paper Sessions PA21-3 PROACTIV
Page 369 and 370:
2015 Paper Sessions addition, four
Page 371 and 372:
2015 Paper Sessions intervention an
Page 373 and 374:
2015 Paper Sessions PA10-5 ATTACHME
Page 375 and 376:
2015 Paper Sessions production, sho
Page 377 and 378:
2015 Paper Sessions (32%) used phar
Page 379 and 380:
2015 Paper Sessions smokers living
Page 381 and 382:
2015 Paper Sessions PA20-3 ‘SOUND
Page 383 and 384:
2015 Paper Sessions flavors used, n
Page 385 and 386:
2015 Paper Sessions attractiveness
Page 387 and 388:
2015 Paper Sessions YIPA-3 NETWORKS
Page 389 and 390:
Poster Session 1 • Thursday, Febr
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
2015 Notes ________________________
Page 453 and 454:
2015 Notes ________________________
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Poster Session 3 • Friday, Februa
Page 501 and 502:
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533 and 534:
Page 535 and 536:
Page 537 and 538:
Page 539 and 540:
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
Page 547 and 548:
Page 549 and 550:
Page 551 and 552:
Page 553 and 554:
Page 555 and 556:
Page 557 and 558:
Page 559 and 560:
Page 561 and 562:
Page 563 and 564:
Page 565 and 566:
Page 567 and 568:
Page 569 and 570:
Page 571 and 572:
Page 573 and 574:
Page 575 and 576:
Page 577 and 578:
Page 579 and 580:
Page 581 and 582:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
Page 607 and 608:
Page 609 and 610:
Page 611 and 612:
Page 613 and 614:
22/1/2015 The deception of measurin
Page 615 and 616:
9/1/2015 The impact of flavor descr
Page 617 and 618:
Page 619 and 620:
Page 621 and 622:
Page 623 and 624:
Page 625 and 626:
Page 627 and 628:
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
Page 637 and 638:
26/6/2015 Verified: formaldehyde le
Page 639 and 640:
E-Cigarettes: implications for harm
Page 641 and 642:
ECs: from risk reduction to harm re
Page 643 and 644:
Exploring ECs harm reversal potenti
Page 645 and 646:
Long effect of smoking abstinence/r
Page 647 and 648:
Exploring harm reduction/reversal p
Page 649 and 650:
Post Cessation Weight Gain in Quitt
Page 651 and 652:
Chronic effect of abstinence/reduct
Page 653 and 654:
Exploring ECs harm reversal potenti
Page 655 and 656:
Effect of abstinence/reduction on S
Page 657 and 658:
Increased prevalence of asthma Mor
Page 659 and 660:
• ECs are effective and safe in R
Page 661 and 662:
Smoking habit and asthma exacerbati
Page 663 and 664:
3.8 FEV1 Improvement from baseline
Page 665 and 666:
FEF25-75 Improvement from baseline
Page 667 and 668:
Methacholine PC20 Improvement from
Page 669 and 670:
Juniper’s ACQ Improvement from ba
Page 671 and 672:
RESPIRATORY SYMPTOMS IN E-CIG USERS
Page 673 and 674:
Prohibition or profit motive? Compe
Page 675 and 676:
Global cigarette consumption - stil
Page 677 and 678:
The Lancet - March 2015 673
Page 679 and 680:
2040 ‘endgame’ - eliminating to
Page 681 and 682:
The standard kit bag (FCTC) 677
Page 683 and 684:
Endgame: How tobacco control sees i
Page 685 and 686:
Prohibitions • No quality standar
Page 687 and 688:
It may be prohibited but is definit
Page 689 and 690:
4. Reduce nicotine in cigarettes 68
Page 691 and 692:
Big Tobacco: half a trillion dollar
Page 693 and 694:
What’s the right thing to do? Rig
Page 695 and 696:
Much safer recreational nicotine de
Page 697 and 698:
Harm reduction categories - risk co
Page 699 and 700:
Global cigarette consumption - stil
Page 701 and 702:
Cigarette consumption continues on
Page 703 and 704:
Hypothetical introduction of new ni
Page 705 and 706:
Not if, how? 701
Page 707 and 708:
Diminishing and negative returns to
Page 709 and 710:
Opportunity not threat Regulator Fi
Page 711 and 712:
Page 713 and 714:
Page 715 and 716:
Page 717 and 718:
2/7/2015 An approach to ingredient
Page 719 and 720:
Page 721 and 722:
Page 723 and 724:
Page 725 and 726:
Page 727 and 728:
Page 729 and 730:
Page 731 and 732:
Page 733 and 734:
R. Tayyarah, G.A. Long / Regulatory
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Research Report Ecigarettes gener
Page 741 and 742:
Measurements Aldehyde levels were m
Page 743 and 744:
A.D. Flouris et al. / Food and Chem
Page 745 and 746:
A.D. Flouris et al. / Food and Chem
Page 747 and 748:
Page 749 and 750:
Page 751 and 752:
Page 753 and 754:
Page 755 and 756:
Page 757 and 758:
Page 759 and 760:
Page 761 and 762:
Page 763 and 764:
Page 765 and 766:
Page 767 and 768:
Page 769 and 770:
Page 771 and 772:
Page 773 and 774:
Page 775 and 776:
Page 777 and 778:
Page 779 and 780:
Page 781 and 782:
Page 783 and 784:
Page 785 and 786:
Page 787 and 788:
Page 789 and 790:
August 2015 Stopping smoking by usi
Page 791 and 792:
August 2015 Stopping smoking by usi
Page 793 and 794:
NIH Public Access Author Manuscript
Page 795 and 796:
Vansickel et al. Page 3 NIH-PA Auth
Page 797 and 798:
Page 799 and 800:
Page 801 and 802:
Page 803 and 804:
Vansickel et al. Page 11 NIH-PA Aut
Page 805 and 806:
Vansickel et al. Page 13 NIH-PA Aut
Page 807 and 808:
Vansickel et al. Page 15 Measure Co
Page 809 and 810:
24/8/2015 JAMA Network | JAMA | Ass
Page 811 and 812:
Page 813 and 814:
Page 815 and 816:
Page 817 and 818:
E-cigarettes: an evidence update A
Page 819 and 820:
E-cigarettes: an evidence update Co
Page 821 and 822:
E-cigarettes: an evidence update Fo
Page 823 and 824:
E-cigarettes: an evidence update Ex
Page 825 and 826:
E-cigarettes: an evidence update ne
Page 827 and 828:
E-cigarettes: an evidence update Su
Page 829 and 830:
E-cigarettes: an evidence update Po
Page 831 and 832:
E-cigarettes: an evidence update In
Page 833 and 834:
E-cigarettes: an evidence update 2.
Page 835 and 836:
E-cigarettes: an evidence update ha
Page 837 and 838:
E-cigarettes: an evidence update
Page 839 and 840:
E-cigarettes: an evidence update
Page 841 and 842:
E-cigarettes: an evidence update Po
Page 843 and 844:
E-cigarettes: an evidence update sm
Page 845 and 846:
E-cigarettes: an evidence update Th
Page 847 and 848:
E-cigarettes: an evidence update Fi
Page 849 and 850:
E-cigarettes: an evidence update Sc
Page 851 and 852:
Page 853 and 854:
Page 855 and 856:
E-cigarettes: an evidence update wh
Page 857 and 858:
Page 859 and 860:
E-cigarettes: an evidence update Ne
Page 861 and 862:
Page 863 and 864:
E-cigarettes: an evidence update O
Page 865 and 866:
E-cigarettes: an evidence update ev
Page 867 and 868:
E-cigarettes: an evidence update sm
Page 869 and 870:
Page 871 and 872:
Page 873 and 874:
Page 875 and 876:
Page 877 and 878:
Page 879 and 880:
Page 881 and 882:
E-cigarettes: an evidence update ni
Page 883 and 884:
Page 885 and 886:
E-cigarettes: an evidence update In
Page 887 and 888:
E-cigarettes: an evidence update As
Page 889 and 890:
E-cigarettes: an evidence update St
Page 891 and 892:
E-cigarettes: an evidence update Du
Page 893 and 894:
E-cigarettes: an evidence update wh
Page 895 and 896:
Page 897 and 898:
E-cigarettes: an evidence update 11
Page 899 and 900:
Page 901 and 902: E-cigarettes: an evidence update 12
Page 903 and 904: E-cigarettes: an evidence update ex
Page 905 and 906: E-cigarettes: an evidence update Ac
Page 907 and 908: E-cigarettes: an evidence update So
Page 917 and 918: E-cigarettes: an evidence update AP
Page 919 and 920: E-cigarettes: an evidence update o
Page 921 and 922: E-cigarettes: an evidence update Ca
Page 923 and 924: E-cigarettes: an evidence update Pa
Page 925 and 926: E-cigarettes: an evidence update Ap
Page 927 and 928: E-cigarettes: an evidence update 3)
Page 929 and 930: E-cigarettes: an evidence update Ex
Page 931 and 932: Pokhrel et al. BMC Public Health (2
Page 941 and 942: That poorer groups face barriers to
Page 943 and 944: 8/9/2015 IASLC Issues New Statement
Page 945 and 946: 8/9/2015 IASLC Issues New Statement
Page 947 and 948: Behavior and E-Cigarette Exposure C
Page 949 and 950: Behavior and E-Cigarette Exposure r
Page 951: Behavior and E-Cigarette Exposure F
Page 955 and 956: Behavior and E-Cigarette Exposure F
Page 957 and 958: Behavior and E-Cigarette Exposure F
Page 959 and 960: Behavior and E-Cigarette Exposure 2
Page 961 and 962: Farsalinos and Le Houezec ingredien
Page 963 and 964: Farsalinos and Le Houezec Dovepress
Page 965 and 966: Farsalinos and Le Houezec used in e
Page 967 and 968: Farsalinos and Le Houezec scientist
Page 969 and 970: Farsalinos and Le Houezec Dovepress
Page 971 and 972: Journal of Chromatography A, 1410 (
Page 973 and 974: E. Marco, J.O. Grimalt / J. Chromat
Page 981 and 982: Funding: This study was supported b
Page 983 and 984: INTRODUCTION Electronic cigarettes
Page 985 and 986: University of California, San Franc
Page 987 and 988: 0.02 N HCl by LC-MS/MS using a meth
Page 989 and 990: of 93.8% (median 99.6%, range 49.0-
Page 991 and 992: The extent to which nicotine from e
Page 993 and 994: particularly concerning for adolesc
Page 995 and 996: REFERENCES 1. King BA, Patel R, Ngu
Page 997 and 998: 28. Henningfield JE, Keenan RM. Nic
Page 999 and 1000: TABLE 1: Demographic characteristic
Page 1001 and 1002: TABLE 3: Nicotine delivered and ret
Page 1003 and 1004:
TABLE 5: Withdrawal and urge to use
Page 1005 and 1006:
Curr Envir Health Rpt DOI 10.1007/s
Page 1007 and 1008:
Curr Envir Health Rpt Fig. 1 Flow d
Page 1009 and 1010:
Curr Envir Health Rpt Observational
Page 1011 and 1012:
Curr Envir Health Rpt Real-world ob
Page 1013 and 1014:
12/10/2015 Une nouvelle étude indi
Page 1015 and 1016:
Ferrari et al. BMC Pulmonary Medici
Page 1017 and 1018:
Page 1019 and 1020:
Page 1021 and 1022:
Page 1023 and 1024:
15/10/2015 What to Advise to Respir
Page 1025 and 1026:
Page 1027 and 1028:
Page 1029 and 1030:
Editorial | Published 16 September
Page 1031 and 1032:
Correspondence E-cigarettes: Public
Page 1033 and 1034:
12/11/2015 Patterns of Electronic C
Page 1035 and 1036:
19/11/2015 Electronic cigarettes in
Page 1037 and 1038:
10.1111/add.13240. Publication Hist
Page 1039 and 1040:
7/12/2015 Highly Reactive Free Radi
Page 1041 and 1042:
Page 1043 and 1044:
Page 1045 and 1046:
Page 1047 and 1048:
Page 1049 and 1050:
Int J Public Health DOI 10.1007/s00
Page 1051 and 1052:
E-cigarettes as smoking cessation a
Page 1053 and 1054:
E-cigarettes as smoking cessation a
Page 1055 and 1056:
1/1/2016 New Study Doesn't Show E
show all

Le mag’

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?